Replies to post #12337 on Inovio Pharmaceuticals Inc (INO)

[cameron12x]

The P2 results were not stellar.

52% was the expected primary endpoint and we only reached 49.5% We didn't miss by much, but a miss is a miss and the market responded correctly. The 40% clearing of the virus was a bonus, but Wall Street doesn't understand the science well enough to understand this. They only look at topline results (similar to earnings).

Still, much will be learned from this trial and I eventually see VGX-3100 making it to P3.